Hiroo Imai

547 total citations
45 papers, 385 citations indexed

About

Hiroo Imai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hiroo Imai has authored 45 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Hiroo Imai's work include Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Hiroo Imai is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Hiroo Imai collaborates with scholars based in Japan, Canada and Greece. Hiroo Imai's co-authors include Chikashi Ishioka, Keigo Komine, Ken Saijo, Masanobu Takahashi, Masahiro Takahashi, Hidekazu Shirota, Shin Takahashi, Kota Ouchi, Hideki Shimodaira and Shunsuke Kato and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Hiroo Imai

42 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroo Imai Japan 12 165 110 94 75 48 45 385
Alessandro Parisi Italy 11 208 1.3× 62 0.6× 119 1.3× 74 1.0× 38 0.8× 56 404
Toshiro Miwa Japan 11 163 1.0× 64 0.6× 123 1.3× 36 0.5× 60 1.3× 43 362
Tenglong Tang China 10 302 1.8× 75 0.7× 65 0.7× 72 1.0× 42 0.9× 20 474
Minehiko Inomata Japan 14 212 1.3× 84 0.8× 170 1.8× 64 0.9× 62 1.3× 54 457
Francesco Agustoni Italy 12 212 1.3× 90 0.8× 171 1.8× 108 1.4× 17 0.4× 54 499
Kenta Kambara Japan 13 165 1.0× 70 0.6× 160 1.7× 36 0.5× 62 1.3× 35 448
Shinji Ohtake Japan 10 112 0.7× 82 0.7× 84 0.9× 125 1.7× 22 0.5× 29 292
Shinichi Yamauchi Japan 12 281 1.7× 118 1.1× 124 1.3× 142 1.9× 35 0.7× 75 540
Breton Roussel United States 8 82 0.5× 62 0.6× 93 1.0× 74 1.0× 49 1.0× 21 327
Xianling Liu China 10 175 1.1× 148 1.3× 62 0.7× 37 0.5× 30 0.6× 33 506

Countries citing papers authored by Hiroo Imai

Since Specialization
Citations

This map shows the geographic impact of Hiroo Imai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroo Imai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroo Imai more than expected).

Fields of papers citing papers by Hiroo Imai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroo Imai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroo Imai. The network helps show where Hiroo Imai may publish in the future.

Co-authorship network of co-authors of Hiroo Imai

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroo Imai. A scholar is included among the top collaborators of Hiroo Imai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroo Imai. Hiroo Imai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Komine, Keigo, et al.. (2026). Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations. Frontiers in Oncology. 16. 1735690–1735690.
2.
Takahashi, Masanobu, Keigo Komine, Kota Ouchi, et al.. (2025). Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database. International Journal of Clinical Oncology. 30(5). 914–925. 1 indexed citations
3.
4.
Imai, Hiroo, et al.. (2024). Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer. Internal Medicine. 63(19). 2667–2671. 1 indexed citations
5.
Saijo, Ken, Kota Ouchi, Keigo Komine, et al.. (2024). Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab. Scientific Reports. 14(1). 28255–28255. 2 indexed citations
6.
7.
8.
Saijo, Ken, Hiroo Imai, Kota Ouchi, et al.. (2023). Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens. Frontiers in Oncology. 13. 1230731–1230731. 3 indexed citations
9.
Hiratsuka, Yusuke, Takayuki Oishi, Mitsunori Miyashita, et al.. (2023). Prognostic awareness in Japanese patients with advanced cancer: a follow-up cohort study. Japanese Journal of Clinical Oncology. 53(5). 410–418. 4 indexed citations
10.
Komine, Keigo, Yoshifumi Kawamura, Kota Ouchi, et al.. (2023). FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. Anticancer Research. 43(12). 5699–5704. 3 indexed citations
11.
12.
Imai, Hiroo, Ken Saijo, Keigo Komine, et al.. (2022). Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study. SHILAP Revista de lepidopterología. 7 indexed citations
13.
Yoshioka, Takashi, Masanobu Takahashi, Yasuhiro Sakamoto, et al.. (2022). Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial. Anticancer Research. 42(4). 2009–2015. 1 indexed citations
14.
Saijo, Ken, Hiroo Imai, Fumiyoshi Fujishima, et al.. (2022). BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation. SHILAP Revista de lepidopterología. 15(2). 762–769. 3 indexed citations
15.
Kawamura, Yoshifumi, Ken Saijo, Hiroo Imai, & Chikashi Ishioka. (2021). Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells. Cancer Science. 112(11). 4711–4721. 6 indexed citations
16.
Takahashi, Masanobu, Keigo Komine, Hiroo Imai, et al.. (2017). Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. PLoS ONE. 12(5). e0176972–e0176972. 11 indexed citations
17.
Imai, Hiroo, Keigo Komine, Shin Takahashi, et al.. (2016). Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma. Chemotherapy. 61(5). 262–268. 10 indexed citations
18.
Imai, Hiroo, Hidekazu Shirota, Akira Okita, et al.. (2015). Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series. Chemotherapy. 61(3). 111–116. 13 indexed citations
19.
Imai, Hiroo, et al.. (2013). Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer. BMC Palliative Care. 12(1). 38–38. 35 indexed citations
20.
Kawai, S., et al.. (2012). Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87. Oncology Reports. 29(1). 13–20. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandro Parisi Breakdown of academic impact, for papers by Toshiro Miwa Breakdown of academic impact, for papers by Tenglong Tang Breakdown of academic impact, for papers by Minehiko Inomata Breakdown of academic impact, for papers by Francesco Agustoni Breakdown of academic impact, for papers by Kenta Kambara Breakdown of academic impact, for papers by Shinji Ohtake Breakdown of academic impact, for papers by Shinichi Yamauchi Breakdown of academic impact, for papers by Breton Roussel Breakdown of academic impact, for papers by Xianling Liu
Rankless by CCL
2026